All In MedTech

FDA Clearance Tracker · P030040-S002

ADVIA CENTAUR HBC IGM READYPACK REAGENTS AND ADVIA CENTAUR HBC IGM QUALITY CONTROL MATERIALS

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Oct 20, 2009 (this decision)Source: openFDAMethods & limitations

PMA supplement

The decision

FDA number
P030040-S002
Device name
ADVIA CENTAUR HBC IGM READYPACK REAGENTS AND ADVIA CENTAUR HBC IGM QUALITY CONTROL MATERIALS
Applicant location
East Walpole, MA
Received
Aug 11, 2008
Decided
Oct 20, 2009
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Change Design/Components/Specifications/Material
Original approval
P030040

Device type

Device class
Class II
Regulation
21 CFR 866.3172

Every decision under product code LOM

FDA's approval statement

As written in FDA's record.

APPROVAL FOR THE TRANSITION OF THE ADVIA CENTAUR HBC IGM ASSAY TO A NEW PLATFORM IN THE CENTAUR FAMILY OF INSTRUMENTS, THE CENTAUR CP. THE DEVICE, AS MODIFIED, WILL BE MARKETED UNDER THE TRADE NAME ADVIA CENTAUR HBC IGM ASSAY AND IS INDICATED FOR:ADVIA CENTAUR HBC IGM READYPACK REAGENTS ON THE CENTAUR CP ANALYZER:THE ADVIA CENTAUR HBC IGM ASSAY IS AN IN VITRO DIAGNOSTIC TEST FOR THE QUALITATIVEDETERMINATION OF IGM RESPONSE TO HEPATITIS B VIRUS CORE ANTIGEN IN HUMAN SERUM ANDPLASMA (EDTA OR LITHIUM OR SODIUM HEPARINIZED) USING THE ADVIA CENTAUR CP SYSTEM.THE ASSAY USES RECOMBINANT HBC ANTIGEN. THIS ASSAY MAY BE USED IN COMBINATION WITHOTHER HEPATITIS B VIRUS (HBV) MARKER ASSAYS TO DEFINE THE CLINICAL STATUS OF KNOWN HBVINFECTED PATIENTS OR CAN BE COMBINED WITH OTHER HBV, HAV (HEPATITIS A VIRUS), AND HCV(HEPATITIS C VIRUS) ASSAYS FOR THE DIAGNOSIS OF PATIENTS PRESENTING SYMPTOMS OF ACUTE VIRAL HEPATITIS. ASSAY PERFORMANCE CHARACTERISTICS HAVE NOT BEEN ESTABLISHED FOR IMMUNOCOMPRO-MISED ORIMMUNOSUPPRESSED PATIENTS, CORD BLOOD, NEONATAL SPECIMENS, INFANTS, OR CHILDREN.ASSAY PERFORMANCE CHARACTERISTICS HAVE NOT BEEN ESTABLISHED WHEN THE ADVIA CENTAUR HBC IGM ASSAY IS USED IN CONJUNCTION WITH OTHER MANUFACTURERS' ASSAYS FOR SPECIFIC HBV SEROLOGICAL MARKERS.ADVIA CENTAUR HBC IGM QUALITY CONTROL MATERIALS ON THE CENTAUR CP ANALYZER:FOR MONITORING THE PERFORMANCE OF THE HBC IGM ASSAY USING THE ADVIA CENTAURSYSTEMS. THE PERFORMANCE OF THE HBC IGM QUALITY CONTROL MATERIAL HAS NOT BEENESTABLISHED WITH ANY OTHER ANTI-HBC IGM ASSAYS.

Source documents

Other decisions for Siemens Healthcare Diagnostics

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.